- Asian Investment Desk
- Banking and Finance
- Banking Regulation
- Capital Markets
- Corporate and Commercial
- Corporate Compliance
- Energy
- Environmental
- ESG | Environmental, Social and Governance
- Fintech
- Fishery
- Forestry
- Immigration
- Infrastructure and Concessions
- Insurance and Reinsurance
- Intellectual Property
- International Trade and Customs
- Labor & Employment
- Life Sciences
- Maritime and Aviation
- Mergers and Acquisitions
- Mining
- Oil & Gas
- Privacy and Data Protection
- Project Development
- Project Finance
- Public Law
- Public Procurement
- Public Services Regulation
- Real Estate Investment
- Restructuring and Insolvency
- Tax
- Telecom, Media & Technology (TMT)
- Venture Capital and Entrepreneurship
- Water Resources and Sanitation
- Wealth Management
Life Sciences Newsletter - July 2025
Themes
CLINICAL TRIALS AND CANNABIS
Update of procedures in the TUPA
Supreme Decree 010-2025-SA approved the new Single Text of Administrative Procedures (TUPA) of the National Institute of Health (INS).
The INS TUPA contains the requirements, deadlines, and fees related to all clinical trial and cannabis licensing procedures carried out by the INS.
The following procedures have been included:
- License for Scientific Research on Cannabis Derivatives for Clinical Trials without Cultivation
- Clinical Trial Authorization
- Modifications to Clinical Trial Authorization
- Amendments to the Research Protocol
- Registration of Research Centers
- Accreditation of Institutional Research Ethics Committees
DIGEMID
GMP Certification in Argentina, China, India, and Paraguay
Through Ministerial Resolutions 452, 453, 457, 467, 468, 469 -2025/MINSA, DIGEMID officials were authorized to travel to Argentina, China, India, and Paraguay to inspect laboratories for the purpose of granting GMP certification (Good Manufacturing Practices).
DRAFT REGULATION
Use of modeling substances
Ministerial Resolution 486-2025-MINSA published the draft Regulation of Law 31014, which regulates the use of modeling substances in body treatments for aesthetic purposes and defines such procedures as medical acts.
The draft Regulation defines modeling substances as "those injectable fillers or biopolymers, polymers, and related resorbable, biodegradable, or permanent substances used in body treatments for aesthetic purposes, included in the list approved by the Ministry of Health, at the proposal of the General Directorate of Medicines, Supplies, and Drugs (DIGEMID)."
The Ministry of Health will receive comments and recommendations on the draft until Tuesday, August 20, 2025, via email at webmaster@minsa.gob.pe.